Ditchcarbon
  • Contact
  1. Organizations
  2. Pluri Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
IL
updated a month ago

Pluri Inc. Sustainability Profile

Company website

Pluri Inc., also known as Pluri Biotech, is a pioneering biotechnology company headquartered in Illinois. Founded in 2016, Pluri has rapidly established itself in the regenerative medicine sector, focusing on innovative cell therapy solutions. The company is renowned for its unique PluriX™ technology, which enables the efficient production of pluripotent stem cells, setting a new standard in the industry. With a strong operational presence across North America and Europe, Pluri Inc. is committed to advancing therapeutic applications in areas such as drug discovery and personalised medicine. The company has achieved significant milestones, including collaborations with leading research institutions, solidifying its position as a key player in the biotechnology landscape. Pluri's dedication to quality and innovation continues to drive its success and influence in the regenerative medicine field.

DitchCarbon Score

How does Pluri Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

23

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Pluri Inc.'s score of 23 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.

29%

Let us know if this data was useful to you

Pluri Inc.'s reported carbon emissions

Pluri Inc., headquartered in Illinois, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Pluri Inc. may still be in the early stages of developing its climate commitments or may not have publicly disclosed its emissions profile. In the context of industry standards, it is essential for companies to establish clear carbon reduction targets and report their emissions transparently to align with global climate initiatives. Without specific emissions data or commitments, Pluri Inc. may face challenges in demonstrating its dedication to sustainability and climate action.

How Carbon Intensive is Pluri Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Pluri Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Pluri Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Pluri Inc. is in IL, which has a low grid carbon intensity relative to other regions.

Pluri Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Pluri Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Pluri Inc.'s Emissions with Industry Peers

Gilead Sciences

US
•
Pharmaceutical Preparation Manufacturing
Updated 4 days ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated about 6 hours ago

CureVac

DE
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

TEI Biosciences Inc.

US
•
Medical, precision and optical instruments, watches and clocks (33)
Updated 26 days ago

Amgen

US
•
Pharmaceutical Preparation Manufacturing
Updated 7 days ago

Regenerative Sciences, Inc.

US
•
Insurance and pension funding services, except compulsory social security services (66)
Updated about 2 months ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251031.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy